Medical Condition News

RSS

Nile announces results of CD-NP Phase 2 study in renally compromised ADHF patients

Nile Therapeutics, Inc. a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced results of its Phase 2 study evaluating its lead compound CD-NP in patients with acute decompensated heart failure (ADHF) and mild to moderate renal insufficiency. Study results demonstrated that multiple doses were characterized as well tolerated with favorable drug activity in this acute patient population.

3 Nov 2010

Talecris announces launch of PROLASTIN-C in Canada

Talecris Biotherapeutics announced today the Canadian launch of PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human])(A1PI), a more concentrated and purified formulation of PROLASTIN®, the only approved alpha1-augmentation therapy in Canada for more than 20 years. PROLASTIN-C delivers twice the active protein per milliliter as PROLASTIN, cutting the infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min.

3 Nov 2010

Atrium completes enrollment in iCAST Atrium Registry Ultrasound Study

Atrium Medical Corporation is pleased to announce that the final patient was recently enrolled in the iCAST™ Atrium Registry Ultrasound Study (iCARUS). This study is a prospective, multi-center clinical trial studying the safety and efficacy of the Atrium iCAST™ Balloon Expandable Covered Stent in patients with occlusive disease of the iliac artery.

2 Nov 2010

Asthmatx presents 2-year results from AIR2 Trial of bronchial thermoplasty in severe asthma

Boston Scientific Corporation today announced that its newly acquired subsidiary, Asthmatx, Inc., presented two-year results from the Asthma Intervention Research 2 (AIR2) Trial demonstrating the long-term safety and effectiveness of bronchial thermoplasty (BT) in adult patients with severe asthma.

2 Nov 2010

Pain Therapeutics awarded $2,000,000 U.S. government research grant

Pain Therapeutics, Inc. announced today that it has been awarded over $2,000,000 in research grants by the U.S. government. These grants are planned to support the Company's on-going biomedical research for nervous system disorders and oncology. Pain Therapeutics expects to receive funding from these research grants now through the end of 2011.

2 Nov 2010

GSK's Revolade receives Japanese approval for treatment of chronic ITP

Ligand Pharmaceuticals Incorporated today announced its partner GlaxoSmithKline was granted approval from the Japanese Ministry of Health, Labour and Welfare for Revolade® (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP).

2 Nov 2010

RegeneRx announces positive results from RGN-259 non-clinical study for Dry Eye Syndrome

RegeneRx Biopharmaceuticals, Inc. today announced the results of its first non-clinical dry eye study using RGN-259, RegeneRx's ophthalmic, preservative-free eye drop for the treatment of Dry Eye Syndrome (DES). In the study, animals were treated with RGN-259, a vehicle control and a positive control, doxycycline.

2 Nov 2010

TriRima shows positive result in food-induced cardiovascular effects associated with MAO inhibitors

CeNeRx BioPharma, Inc., today announced that a new formulation of TriRima, its lead agent for treatment resistant depression, showed excellent safety in a study designed to test whether it is free of the food-induced cardiovascular effects associated with conventional MAO inhibitors.

2 Nov 2010

Scientists investigate link between nature and reduction in stress levels

Scientists at the University of Essex are embarking on a new project to build on their existing research into the benefits of enjoying the great outdoors.

2 Nov 2010

Lactic acid levels in brain linked to aging process

Researchers at Karolinska Institutet have shown that they may be able to monitor the aging process in the brain, by using MRI technique to measure the brain lactic acid levels. Their findings suggest that the lactate levels increase in advance of other aging symptoms, and therefore could be used as an indicator of aging and age-related diseases of the CNS.

2 Nov 2010

Molecular imaging technique pinpoints changes that take place in injured brain

Results from a study published in the November issue of The Journal of Nuclear Medicine (JNM) show that powerful imaging techniques positron emission tomography (PET) fused with magnetic resonance imaging (MRI) are helping researchers better understand the long-term functional and structural changes that take place after traumatic brain injury (TBI).

2 Nov 2010

Liver-related mortality ranks #4 for people between ages of 45 and 64

Statistics from the Centers for Disease Control and Prevention (CDC) rank mortality related to chronic liver disease and cirrhosis as the 12th most common cause of death in adults in the U.S. Using a modified definition that includes diseases such as viral hepatitis, liver cancer and obesity-related fatty liver disease, Mayo Clinic-led researchers have found that liver-related mortality is as high as fourth for some age groups, and eighth overall.

2 Nov 2010

Autism Consortium begins new therapeutic initiative on Translational Medicine

The Autism Consortium, an innovative Boston area collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), announced that it will begin a new initiative on Translational Medicine and Autism Therapeutics. The new focus was introduced at the Consortium's fifth annual symposium held October 26th, 2010, at Harvard Medical School in Boston.

2 Nov 2010

Elekta presents solutions for ultimate precision in cancer care at ASTRO Meeting

Elekta presented solutions for ultimate precision in cancer care at an Investor Meeting in conjunction with the 52nd annual American Society for Radiation Oncology (ASTRO) Meeting, in San Diego. Elekta also discussed the market drivers in established and emerging markets, and explained its strategy for sustainable profitable growth.

From Elekta 2 Nov 2010

ArcticDx develops test to determine inherited risk for AMD

Established in 2007 and based in Toronto, ArcticDx has developed a test, Macula Risk-, the first of its kind and specifically designed to determine one's inherited risk for age-related macular degeneration (AMD), the most common form of acquired blindness in the developed world, affecting over 10% of individuals. ArcticDx will use the PBDF investment to undertake studies in support of a planned filing for Food and Drug Administration (FDA) approval for Macula Risk.

2 Nov 2010

New wiring diagram shows how brain organizes information

University of Utah (U of U) medical researchers have uncovered a wiring diagram that shows how the brain pays attention to visual, cognitive, sensory, and motor cues. The research provides a critical foundation for the study of abnormalities in attention that can be seen in many brain disorders such as autism, schizophrenia, and attention deficit disorder.

2 Nov 2010

Researchers explain how adiponectin prevents stress-induced damage in heart

One of the many advantages of maintaining a normal body weight is having healthy fat, which in turn supports a healthy heart. Fat tissue is increasingly seen as more than just a storage depot - it's also an active secretory organ that normally produces high levels of a cardioprotective hormone called adiponectin. How adiponectin protects the hearts of healthy people has long been a mystery, and now a team led by Barbara Ranscht, Ph.D. and Pilar Ruiz-Lozano, Ph.D. at Sanford-Burnham Medical Research Institute (Sanford-Burnham) reveals that the protein T-cadherin is the receptor that anchors adiponectin to heart cells.

2 Nov 2010

LSU Health Sciences Center New Orleans awarded top Psychiatric Services honor

The Department of Psychiatry at LSU Health Sciences Center New Orleans has been given the 2010 Gold Achievement Award by the American Psychiatric Association for a program credited by the St. Bernard Parish Public School System as key to reopening schools and recovery of the community after Hurricane Katrina. This is the top Psychiatric Services honor bestowed by the world's largest psychiatric organization.

2 Nov 2010

New targeted therapy shows positive results in patients with lung cancer

A UC Irvine oncologist's work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine.

2 Nov 2010

Eye transformer impacts JAK/STAT-signaling pathway response with microbial challenge

Scientists are keeping their eye on a new discovery published in the November 2011 print issue of the FASEB Journal (http://www.fasebj.org) that explains what causes some genes to go out of control. Scientists have identified a "cellular switch," called eye transformer, that controls the flow of information from chemical signals outside of the cell to genes in the cell nucleus.

2 Nov 2010